

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/35834 A1

(51) International Patent Classification⁷: A61B 17/064, 17/068, 17/04

(21) International Application Number: PCT/US00/30038

(22) International Filing Date:
1 November 2000 (01.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/432,575 12 November 1999 (12.11.1999) US

(71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US];
One Scimed Place, Maple Grove, MN 55331-1566 (US).

(72) Inventors: PUGSLEY, Charles, H., Jr.: 31 Clark Circle,
Pelham, NH 03076 (US). GELLMAN, Barry, N.: 19 Pebblebrook Road, North Easton, MA 02356 (US).

(74) Agents: BRAINARD, Charles, R. et al.; Kenyon & Kenyon, Suite 700, 1500 K Street, N.W., Washington, DC 20005 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GERD TREATMENT APPARATUS AND METHOD



WO 01/35834 A1



(57) Abstract: The present invention includes a method and apparatus for adhering tissue to one another. In an embodiment of the present invention the two tissues to be joined, for example the lower esophagus (110) and the fundus of the stomach (330), are first placed adjacent to one another. Next a first restraint (220) is placed near the outside surface (325) of one of the tissues and a second restraint (200) is placed near the outside surface of the other tissue (310). An irritant (210) is then placed between the two adjacent tissues. The restraints (220, 200), and consequently the tissue surfaces, are then drawn together. As the touching irritated tissue surfaces heal they will become bonded to one another and their need for the mechanical fastening of the restraints, to secure them together, will be diminished.

GERD TREATMENT APPARATUS AND METHOD

Field of the Invention

5 The present invention relates to the treatment of Gastro Esophageal Reflux Disease (GERD). More specifically the present invention provides a method and an apparatus for enhancing the function of the lower esophageal sphincter to preclude the occurrence of Gastro Esophageal Reflux Disease.

10 Background of the Invention

Gastro Esophageal Reflux occurs when stomach acid splashes back through the lower esophageal sphincter into the esophagus. Highly acidic in nature, the stomach acid irritates the esophagus causing pain and discomfort. This discomfort manifests itself as heartburn, or in severe cases, as chest pains. A prolonged exposure to stomach acid will damage the esophagus and can contribute to other esophageal ailments such as Barrett's Esophagus.

15 Gastro Esophageal Reflux Disease, the repeated occurrence of gastro esophageal reflux, stems from an incompetent Lower Esophageal Sphincter (LES), one that has begun to inadequately close. No longer does the failing lower sphincter prevent stomach acid from splashing back into the esophagus as would a properly functioning lower sphincter. Instead, as digestion in the stomach progresses, the acid required to break down the stomach's contents refluxes, unrestricted by the lower esophageal sphincter, into the lower esophagus during each digestive cycle.

Both non-surgical and surgical methods of treatment are available to attempt to provide relief from the disease. Medications that diminish or even eliminate the acidic secretions in the stomach can be proscribed and administered to treat the sphincter dysfunction. While these medications may provide short term relief, they

5 do not address the underlying problem of the malfunctioning sphincter. Surgery, another available treatment, seeks to address the underlying problem. One available surgical procedure, fundoplication, involves wrapping the fundus of the stomach around, and to, the lower esophageal sphincter in support of the sphincter. More specifically, as digestion begins to take place, gases begin to develop in the stomach.

10 The amount and volume of gas increases as digestion progresses. Eventually, enough gas is present in the stomach to inflate and expand the fundus. Now wrapped around the esophagus, as the fundus inflates and expands it places pressure on the lower sphincter in support of the sphincter's complete closure. As the digestive cycle concludes the gases in the stomach subside and the closing pressure

15 on the sphincter dissipates, once again allowing the sphincter to open.

Fundoplication has proven to be an effective method of treatment but not without some cost and risks. When the operation is performed, through an incision in the abdominal cavity (illustrated at 120 in Fig. 1), it is a significant one, often requiring one week of hospital stay and four to six weeks of additional recovery.

20 Moreover, being performed in the abdominal cavity, the operation carries along with it the usual risks of abdominal surgery as well as the intraoperative risks associated with working near the esophagus and the cardia.

Other methods of performing a fundoplication are also known. For example, laproscopic procedures have been used to perform the operation. Here, rather than

25 making an incision in the abdominal cavity, several surgical cannulas are inserted into the abdomen in various places. The surgery is then performed through these cannula portals by the surgeon as opposed to through a large incision in the abdominal cavity as would be utilized in a full abdominal fundoplication. Once completed, the recovery time from this process involves several days of hospital stay

and a week or more of outpatient recovery time.

In another known approach, endoluminal procedures are used in conjunction with an abdominal incision to perform a fundoplication. Here, an invagination device containing several retractable needles is inserted into the mouth and down the esophagus to be used in conjunction with a manipulation and stapling device remotely inserted through an opening in the abdominal cavity. The fundoplication is performed by these devices with fasteners being employed to secure the fundus into its new position. In addition to requiring an abdominal breech, this procedure utilizes surgical staples that, due to the highly acidic nature of stomach acid, have not proven to be completely effective over time. Exposed to the stomach acid the staples can erode away thereby requiring a second identical procedure be performed. Other approaches also exist, but these too contain the same disadvantages – additional incisions, or mechanical fasteners susceptible to erosion from the stomach acid, or both.

It would, therefore, be desirable to have an apparatus and method for performing fundoplication wherein no additional incisions into the body would be required and wherein the risk of the fundus becoming dislodged due to the undermining of the integrity of the surgical fasteners would be diminished.

20 Summary of the Invention

The present invention includes a method and apparatus for adhering tissue to one another. In an embodiment of the present invention the two tissues to be joined, for example the lower esophagus and the fundus of the stomach, are first placed adjacent to one another. Next, a first restraint is placed near the outside surface of one of the tissues and a second restraint is placed near the outside surface of the other tissue. An irritant is then placed between the two adjacent tissues. The restraints, and consequently the tissue surfaces, are then drawn together. As the touching irritated tissue surfaces heal they will become bonded to one another and their need for the mechanical fastening of the restraints, to secure them together, will

be diminished.

Brief Description of the Drawings

Fig. 1 illustrates a patient with an incision in the abdominal cavity as
5 previously known.

Fig. 2A illustrates the distal end of the pointed carrier in accordance with an
embodiment of the present invention.

10 Fig. 2B illustrates a cross-sectional view as taken along line 2B-2B of Fig.
2A.

Fig. 2C illustrates an unfolded first anchor in accordance with an
embodiment of the present invention.

15 Fig. 2D illustrates an unfolded first anchor after it has entered the stomach in
accordance with an embodiment of the present invention.

Fig. 2E illustrates a nitinol wire before it has been exposed to the body heat
20 of the patient in accordance with an embodiment of the present invention.

Fig. 2F. illustrates a nitinol wire after it has been exposed to the body heat of
the patient in accordance with an embodiment of the present invention.

25 Fig. 3 illustrates the pointed carrier after it has punched through the lower
esophageal wall and the fundal wall in accordance with an embodiment of the
present invention.

Fig. 4 illustrates an embodiment of the present invention wherein the fundal

wall is being pulled against the lower esophagus.

Fig. 5 illustrates an embodiment of the present invention wherein a second anchor has been deployed.

5

Fig. 6 illustrates an embodiment of the present invention wherein a third anchor has been deployed.

Fig. 7 illustrates an embodiment of the present invention wherein the
10 pointed carrier is being removed from the esophagus.

Fig. 8 illustrates the final position of anchors in accordance with an
embodiment of the present invention.

15 Fig. 9 illustrates a cross-sectional view as taken along line 9-9 of Fig. 8.

Fig. 10 illustrates a cross-sectional view as taken along line 10-10 of Fig. 8.

Detailed Description

20 The present apparatus and method can be used in the endoluminal treatment of Gastro Esophageal Reflux Disease. Fig. 1 illustrates a patient's body 100 with an upper esophagus 140, a lower esophagus 110, a stomach 150, and a fundus 130 as is previously known.

Figs. 2A through 2F illustrate a pointed carrier 215 with anchors 205, 210, 25 and 220 contained therein, as employed in an embodiment of the present invention. The pointed carrier 215 has a proximal end (not shown) and a distal pointed end 225. After securing the esophageal pathway, the pointed carrier 215, which may be 50 centimeters or more in length, is inserted, by the surgeon, into the patient's body 100, down the esophagus 140. The proximal end of the pointed carrier 215 (not

shown) remains outside of the patient's body throughout the entire procedure for controlling and manipulating the pointed carrier. No incisions are required in performing the procedure as access into the esophagus is gained by the surgeon through the mouth (not shown). However, should a passageway through the mouth 5 be unavailable, the pointed carrier can be inserted into the lower esophagus through several alternative surgical methods, including an incision in the trachea, as would be evident to those of skill in the art.

Fig. 2A illustrates the lower end of the pointed carrier 215 used in the present invention. The pointed carrier 215 terminates at a distal pointed end 225 sharp 10 enough and strong enough to punch through the lower esophagus and the fundal wall of the stomach during the performance of the procedure. As is evident, the pointed carrier 215 is hollow and contains several surgical anchors or restraints. The first anchor 220, the second anchor 210, and the third anchor 205, are all located within the pointed carrier and are all impregnated with collagen to encourage tissue 15 ingrowth and prompt recovery. The three anchors are also all affixed to a guy wire 200 which may be made from nitinol. These surgical anchors or restraints can vary in shape, size, and material. They can be circular, triangular, or any other shape and may be made from Meadox Mesh®, wire, genetically engineered tissue matched to the patient's tissue type or some other suitable material as will be apparent to one of 20 skill in the art. The anchors should, however, have properties that allow them to fit inside the pointed carrier while remaining strong enough to grab, move, and support the organs and tissue in accordance with the steps described below.

The second anchor 210 and the third anchor 205 in Fig. 2A are slidably mounted on the guy wire 200. The first anchor 220 is permanently affixed to the 25 distal end of the guy wire 200 by a securing button 260 (shown in Fig. 2B). This first anchor may rotate about the guy wire 200 but must be secured to it; able to withstand the pulling and anchoring forces placed upon it during the procedure. Knobs 270 are present on the guy wire to maintain spacing between each of the three anchors during the procedure. The knobs 270 are sized so that the second anchor

210 and the third anchor 205 maintain their spacing along the guy wire 200 during the procedure until they are pushed over the knob 270 and utilized within the body.

Fig. 2B is a cross-section as taken along line 2B-2B of Fig. 2A illustrating the leading tip of the first anchor 220 as loaded into the pointed carrier 215. Fig. 2B 5 illustrates the outer surface 240 of the pointed carrier 215, the inner surface 235 of the pointed carrier 215, and button 260. Button 260 is attached to the distal tip of the guy wire 200 and firmly secures the first anchor 220 to the guy wire 200.

Fig. 2C is an illustration of the first anchor 220 before it has been folded to fit into the pointed carrier 215. Nitinol wires 250 and the dashed fold lines 245 are 10 clearly visible. Each anchor 220, 210, and 205 is folded in half and then in half again before they are loaded into the pointed carrier 215. The anchors and guy wire may be loaded by the surgeon before the procedure is to begin or they may be pre-loaded into the pointed carrier 215 by the manufacturer.

Fig. 2D is an illustration of anchor 220 after it has been deployed from the 15 pointed carrier 215 into the body wherein the heat generated by the body has caused the previously straight nitinol wires 250 to bend into spiral patterns 255 having more rigid structural properties. Embedded into the first anchor 220 and the third anchor 205, these wires provide structural reinforcement for the anchors which must withstand severe forces both during the procedure and after they are secured in 20 place.

Fig. 2E illustrates the nitinol wire 250 before the anchor has been exposed to the patient's body heat.

Fig. 2F illustrates the nitinol wire 250 in a spiral pattern 255 after the anchor 25 has been exposed to the patient's body heat causing the wire to curl and become more rigid.

A method of practicing the instant invention will now be further described. As is evident Fig. 3 illustrates the step of initially punching through the lower esophagus 110, the abdominal cavity 160 and the fundal wall 330, and into the stomach cavity 335. Carrying the three anchors, the pointed carrier 215 is

positioned in the lower esophagus 110 by the surgeon from the pointed carrier's proximal end (not shown) using endoluminal visioning systems or other techniques known in the art. Then, having correctly positioned the pointed end 225, the surgeon forces or punches the carrier through the lower esophagus 110, through the 5 abdominal cavity 160, through the fundal wall 330, ultimately coming to rest in the stomach cavity 335. After the pointed end 225 enters the stomach cavity 335, the first anchor 220 is deployed by manipulating the guy wire 200 at the proximal end of the pointed carrier 215, outside the patient's body 100. Once deployed, the first anchor 220 unfolds along the fold lines 245 to its original circular shape and the 10 nitinol wires, now fully exposed to the body's temperature, coil into a spiral pattern 255 to add rigidity to the first anchor 220. The second anchor 210 and the third anchor 205 remain in the pointed carrier 215 for later deployment and use.

As shown in Fig. 4, the pointed carrier 215 is then retracted back through the fundus into the lower esophagus. The first anchor 220, tethered to the guy wire 200, 15 remains in the stomach cavity 335. The guy wire 200 is then reeled in, to first pull the first anchor 220 back, up against the inner wall of the fundus, and then to pull and lift the fundal wall 330 up against the outer wall of the esophagus 315. After the outer wall of the esophagus 315 and the outer wall 320 of the fundus 330 touch, the guy wire 200 is then released to allow the outer wall 320 of the fundus 330 to 20 sag away from the outer wall 315 of the lower esophagus 110, thereby creating a void 500 (shown in Fig. 5) between the fundus 330 and the outer wall 315 of the lower esophagus 110.

After the fundus 330 sags back away from the lower esophageal wall 110, the pointed carrier 215 is pushed down, back through the lower esophageal wall 110, 25 until the pointed tip is located in the void 500 between the outer fundal surface 320 and the outer wall 315 of the lower esophagus. As is evident from Fig. 5, the second anchor 210 is then deployed from the pointed carrier 215. It is deployed through the manipulation of the guy wire 200 at the proximal end of the pointed carrier 215 by the surgeon. Upon release from the pointed carrier, the second anchor 210, saturated

with a sclerosing agent, and not containing any nitinol wires, unfolds. The second anchor does not need to contain the nitinol wires because it will not be exposed to the same level of force that will be placed upon the first and third anchors. The first and third anchors ultimately serve as restraints, compressing the fundal wall and the
5 lower esophagus against each other. They, therefore, must be reinforced to withstand the uncompressing and expanding forces placed upon them in their final position. Conversely, the second anchor, which will ultimately be disposed between the other two anchors in its final position, will not be subjected to the same level of force and, consequently, does not require the nitinol wires be placed within it to
10 reinforce it.

Fig. 6 illustrates the next step wherein the pointed carrier 215 is retracted back through the esophageal wall into the lower esophagus 110. The guy wire 200 is then reeled in, first bringing the first anchor 220 tight against the inner wall 325 of the fundus 330 and then bringing the second anchor 210 tight against the outer wall
15 320 of the fundus 330 and the outer wall 315 of the lower esophagus 110.

The second anchor 210, previously saturated with a sclerosing agent, now comes in contact with the outer wall 320 of the fundus 330 and the outer wall 315 of the lower esophagus 110, irritating both surfaces, the surrounding tissue, and the sclerosis of both the esophagus and the fundus (not shown).

20 The third anchor 205 is then deployed. Once deployed, the third anchor 205 is maneuvered to the inside wall of the lower esophagus to push and draw the esophageal wall and the fundal wall between the three anchors.

Fig. 7 illustrates all three anchors after the third anchor has been placed parallel to the others, sandwiching the fundal wall and the esophageal wall. Once the anchors
25 are drawn together, the pointed carrier is removed. The anchors are then locked in place by either crimping the wire, snapping a band over the wire or performing some other endoscopic procedure known to one of skill in the art. Once the anchors are locked in place the guy wire is cut and the unneeded portion is removed from the patient, once again through an endoscopic procedure known to one of skill in the art.

The three anchors are pulled tightly together, primarily to support the fundus, and secondarily to promote the bonding of tissue resulting from the irritant placed on the second anchor and the collagen impregnating all three anchors. The tissue irritated by the sclerosing agent and exposed to the collagen will promote tissue ingrowth between 5 the stomach and the esophagus. Over time the nitinol guy wire and the anchors may dissipate leaving the ingrown tissues of the stomach and esophagus to be the sole bond between the esophagus and the fundus.

Alternatively, rather than impregnating all three anchors with collagen, the anchors may instead be made from genetically engineered tissue designed to match the 10 tissue of the patient. These anchors, made from the genetically engineered tissue, like the collagen impregnated anchors, will promote the ingrowth and bonding of the fundus and the esophagus after deployment within the body.

Fig. 8 is an illustration of the first, second, and third anchors locked together after the method described above, an embodiment of the present invention, has been 15 performed. As is evident, when the procedure is completed, the first and the third anchors border the fundus and the lower esophagus and serve as a support to hold them together. As is also evident, the knob 260 prevents the first anchor from slipping off the guy wire and the crimp 800, made by the surgeon during the procedure, prevents the third anchor from slipping off the guy wire.

20 Fig. 9 is a cross-section as taken along line 9-9 of Fig. 8, illustrating the three anchors 205, 210, 220, the inner wall of the esophagus and the fundal wall 330 being sandwiched between the three anchors at the completion of the procedure. As will be recognized by one of skill in the art, the lower esophagus's circular cross-section requires that numerous anchors be placed in it to secure the fundus around the entire 25 outer circumference of the lower esophagus. Fig. 9, therefore, illustrates an example of a single completed procedure, one of many that will be necessary to complete a full fundoplication. The actual number of anchors or restraints required varies depending on local conditions and remains within the discretion of the surgeon performing the procedure.

Fig. 10 is a cross-section, as taken along line 10-10 of Fig. 8, illustrating the esophagus and the fundus secured and positioned in accordance with an embodiment of the present invention. As is evident, multiple anchoring systems have been employed to properly secure the fundus to the lower esophagus.

5 In another embodiment of the present invention, rather than using the second anchor to carry the irritating agent, the irritating agent can be squirted into place by the Endoscopist during the procedure. In this embodiment rather than having three anchors as shown in Fig. 2A only two anchors would be disposed along the guy wire 200 of Fig. 2A. After the fundus and the lower esophagus have touched rather than deploying the
10 second anchor 210 as shown in Fig. 5, an irritant, such as a sclerosing agent, would be squirted down the pointed carrier 215 between the fundal wall and the esophageal wall to soak the surfaces of the organs that contact each other. Now bathed in irritant, the organs are then drawn together until they touch. Then the last anchor is deployed in the same manner as shown in Fig. 6 for the third anchor 205. The two anchors are then
15 drawn together to pull the irritant soaked surfaces against one another. Once the soaked surface are pulled together the anchors are locked in place to maintain contact between the surfaces. As the irritated tissues heal the contacting surfaces will adhere to one another and the need for the surgical anchors, to hold them together, will be diminished.

As described above, a method and apparatus for curing Gastro Esophageal Reflux Disease is provided. The disclosed embodiments are illustrative of the various ways in which the present invention may be practiced. Other embodiments can be implemented by those of skill in the art without departing from the spirit and scope of the present invention.

What Is Claimed Is:

- 1 1. A method for adhering a first tissue having a first surface and a second surface to
2 a second tissue having a first surface and a second surface comprising:
3 positioning the first surface of the first tissue adjacent to the first surface
4 of the second tissue;
5 positioning a first restraint adjacent to the second surface of the first
6 tissue;
7 positioning a second restraint adjacent to the second surface of the second
8 tissue;
9 placing an irritant between the first surface of the first tissue and the first
10 surface of the second tissue;
11 drawing said first restraint and the first surface of the first tissue towards
12 said second restraint and the first surface of the second tissue.

- 1 2. The method of claim 1 wherein said placing step includes the sub-steps of:
2 placing said irritant on a third restraint;
3 placing said third restraint between the first surface of the first
4 tissue and the first surface of the second tissue.

- 1 3. The method of claim 1 wherein said irritant is a sclerosing agent.

- 1 4. The method of claim 1 wherein said first restraint and said second restraint are
2 made from genetically engineered tissue.

- 1 5. The method of claim 1 further comprising:
2 securing said first restraint and said second restraint together.

- 1 6. A method for connecting bodily organs comprising:

2 providing a first surgical anchor, a second surgical anchor, and a third
3 surgical anchor;

4 placing a first organ between said first surgical anchor and said second
5 surgical anchor;

6 placing a second organ between said second surgical anchor and said
7 third surgical anchor; and,

8 drawing said first surgical anchor, the first organ, said second surgical
9 anchor, the second organ, and said third surgical anchor together.

1 7. The method of claim 6 wherein said second surgical anchor contains an irritating
2 agent.

1 8. The method of claim 7 wherein said irritating agent is a sclerosing agent.

1 9. The method of claim 6 wherein each of said surgical anchors contain collagen.

1 10. The method of claim 6 wherein said first surgical anchor and said third surgical
2 anchor become more rigid upon release into the bodily organ.

1 11. The method of claim 6 wherein one of said surgical anchors are made from
2 genetically engineered tissue.

1 12. The method of claim 10 wherein said guy wire, said first surgical anchor, and
2 said third surgical anchor each contain nitinol.

1 13. A method for repairing the lower esophageal sphincter comprising the steps of:
2 inserting a pointed carrier containing a first anchor, a second anchor, and
3 a third anchor into an esophagus having an upper end, a lower end, and an outside
4 surface;

5 punching said pointed carrier through the lower end of the esophagus into
6 a stomach having a fundal wall with an interior surface and an exterior surface;
7 deploying said first anchor through the lower end of the esophagus
8 through the fundal wall into the stomach;
9 deploying said second anchor between the outside surface of the lower
10 end of the esophagus and the exterior surface of the fundal wall;
11 deploying said third anchor inside the lower end of the esophagus; and
 drawing said first anchor, the esophageal wall, said second anchor, the
fundal wall and said third anchor toward each other; and securing said first anchor, the
esophageal wall, said second anchor, the fundal wall and said third anchor together.

1 14. The method of claim 13 wherein said second anchor is pre-treated with an
2 irritating agent.

1 15. The method of claim 13 wherein each of said anchors is made from genetically
2 engineered tissue.

1 16. The method of claim 13 further comprising the steps of:
2 inserting an endoscope having a proximal end and a distal end into said
3 esophagus; and,
4 inserting said pointed carrier into said proximal end of said endoscope.

1 17. The method of claim 13 further comprising the step of mounting said first
2 anchor, said second anchor and said third anchor onto a guy wire.

1 18. The method of claim 13 wherein said first anchor, said second anchor, and said
2 third anchor each contain collagen.

1 19. The method of claim 17 wherein said guy wire, said first anchor, and said third

2 anchor each contain nitinol.

1 20. The method of claim 13 wherein said pointed carrier is a hypotube.

1 21. The method of claim 14 wherein said irritating agent is a sclerosing agent.

1 22. A device for repairing the lower esophageal sphincter comprising:
2 a pointed carrier containing a first anchor and a second anchor;
3 said second anchor containing an irritating agent.

1 23. The device of claim 22 wherein said irritating agent is a sclerosing agent.

1 24. The device of claim 22 wherein said first anchor, and said second anchor each
2 contain collagen.

1 25. The device of claim 22 wherein one of said anchors is made from genetically
2 engineered tissue.

1 26. The device of claim 22 wherein said pointed carrier is a hypotube.

1 27. The device of claim 22 further comprising a guy wire connecting said first
2 anchor, and said second anchor.

1 28. The device of claim 27 wherein said guy wire, said first anchor, and said second
2 anchor each contain nitinol.

1 29. A system for endoluminally treating Gastro Esophageal Reflux Disease, the
2 system comprising:
3 a sharp device containing a first anchor, and a second anchor containing

4 an irritating agent, and a third anchor; and,
5 a means for manipulating said anchors.

1 30. The system of claim 29 wherein said irritating agent is a sclerosing agent.

1/7




FIG. 1
(PREVIOUSLY KNOWN)

SUBSTITUTE SHEET (RULE 26)

2 / 7




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D



FIG. 2E



FIG. 2F

3/7




FIG. 3

SUBSTITUTE SHEET (RULE 26)




FIG. 4




FIG. 5

SUBSTITUTE SHEET (RULE 26)




FIG. 6




FIG. 7

SUBSTITUTE SHEET (RULE 26)

6 / 7




FIG. 8




FIG. 9

SUBSTITUTE SHEET (RULE 26)

7/7




FIG. 10

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/30038

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61B17/064 A61B17/068 A61B17/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 571 116 A (BOLANOS ET AL.) 5 November 1996 (1996-11-05) abstract; figures 5A-15 column 3, line 28-35 column 6, line 62 -column 7, line 12 column 8, line 12-20 ---	22,29
A	WO 99 22649 A (SYMBIOSIS CORPORATION) 14 May 1999 (1999-05-14) abstract; figures. ---	22,29
A	EP 0 585 476 A (UNITED STATES SURGICAL CORPORATION) 9 March 1994 (1994-03-09) page 4, line 25 page 6, paragraphs 2,3 ---	22,29
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

2 February 2001

Date of mailing of the international search report

09/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Giménez Burgos, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/30038

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 464 480 A (AMERICAN CYANAMID COMPANY) 8 January 1992 (1992-01-08) abstract; figures ----	22,29
P, X	WO 99 60931 A (BOSTON SCIENTIFIC LIMITED) 2 December 1999 (1999-12-02) the whole document ----	22,29
P, X	WO 00 57796 A (ROSENBLATT) 5 October 2000 (2000-10-05) the whole document -----	22,29

INTERNATIONAL SEARCH REPORT

Information on patent family members				International Application No	
Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
US 5571116 A	05-11-1996	US US	5676674 A 5897562 A	14-10-1997 27-04-1999	
WO 9922649 A	14-05-1999	US AU EP	6086600 A 1295499 A 0969770 A	11-07-2000 24-05-1999 12-01-2000	
EP 0585476 A	09-03-1994	CA US	2074924 A 5447966 A	06-02-1993 05-09-1995	
EP 0464480 A	08-01-1992	US US AT AU AU CA DE DE JP KR	5041129 A 5269809 A 120349 T 653346 B 8010191 A 2046010 A 69108460 D 69108460 T 4231946 A 178358 B	20-08-1991 14-12-1993 15-04-1995 29-09-1994 02-01-1992 03-01-1992 04-05-1995 07-12-1995 20-08-1992 01-04-1999	
WO 9960931 A	02-12-1999	US AU	6113609 A 3725699 A	05-09-2000 13-12-1999	
WO 0057796 A	05-10-2000	NONE			